,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-01-30 02:07:00,"Warner Chilcott ( WCRX ) recently presented disappointing guidance for 2012 based primarily on the assumption of continued sales erosion of its osteoporosis drug, Actonel.",0.02295614592730999,0.9604448676109314,0.016599001362919807,negative,-0.9374887347221375
1,2012-01-30 02:07:00,The Irish company expects to earn in the range of $3.60-$3.70 per share (on an adjusted basis) on revenues between $2.5 billion-$2.6 billion.,0.23632143437862396,0.013402065262198448,0.7502765655517578,neutral,0.22291937470436096
2,2012-01-30 02:07:00,The projections were below the Zacks Consensus revenue ($2.68 billion) and earnings ($4.00 per share) estimates.,0.017472485080361366,0.9636123776435852,0.01891505718231201,negative,-0.9461398720741272
3,2012-01-30 02:07:00,We remind investors that Actonel (acquired from Procter & Gamble Company ( PG ) in 2009) went off-patent in Western Europe in late 2010 thus significantly hampering revenues at Warner Chilcott.,0.021151185035705566,0.9675484299659729,0.011300399899482727,negative,-0.9463972449302673
4,2012-01-30 02:07:00,Actonel accounted for approximately 70% of the revenues generated by Warner Chilcott from the Western European markets in 2010.,0.036454346030950546,0.007307232357561588,0.9562383890151978,neutral,0.029147114604711533
5,2012-01-30 02:07:00,"Moreover, the contraction of the US bisphosphonate market is also expected to hamper US Actonel sales in 2012.",0.019273020327091217,0.9673545956611633,0.013372313231229782,negative,-0.9480815529823303
6,2012-01-30 02:07:00,"However, Warner Chilcott expects products such as Lo Loestrin FE (oral contraceptive), Atelvia (osteoporosis), Estrace Cream (hormone therapy) and Asacol (ulcerative colitis) to perform well in 2012.",0.9130292534828186,0.013185051269829273,0.07378562539815903,positive,0.899844229221344
7,2012-01-30 02:07:00,"The company expects selling, general and administrative (SG&A) expense in 2012 in the range of $800 - $850 million (2011 expectation $925-$975 million).",0.022199120372533798,0.23491771519184113,0.7428832054138184,neutral,-0.21271859109401703
8,2012-01-30 02:07:00,Research and development (R&D) expenses in 2012 are expected in the range of $110 - $130 million (same as 2011 expectations).,0.04708871990442276,0.09721295535564423,0.8556984066963196,neutral,-0.050124235451221466
9,2012-01-30 02:07:00,"Apart from providing guidance for 2012, Warner Chilcott reaffirmed its previous guidance for 2011.",0.5000001192092896,0.020845158025622368,0.47915467619895935,positive,0.4791549742221832
10,2012-01-30 02:07:00,Warner Chilcott expects 2011 revenues in the range of $2.7 -$2.8 billion.,0.06757312268018723,0.005902677308768034,0.9265241622924805,neutral,0.061670444905757904
11,2012-01-30 02:07:00,2011 adjusted earnings are projected in the range of $3.70-$3.80 per share.,0.04329380765557289,0.00873100757598877,0.947975218296051,neutral,0.03456280007958412
12,2012-01-30 02:07:00,The Zacks Consensus Estimate for 2011 hints at earnings of $3.77 per share on revenues of $2.74 billion.,0.15597331523895264,0.016538064926862717,0.8274886012077332,neutral,0.13943524658679962
13,2012-01-30 02:07:00,The company intends to disclose its fourth quarter and full year 2011 financial results in late February this year.,0.017518414184451103,0.00772737804800272,0.9747542142868042,neutral,0.009791036136448383
14,2012-01-30 02:07:00,We currently have a Neutral recommendation on Warner Chilcott in the long run.,0.025588184595108032,0.13572457432746887,0.8386873006820679,neutral,-0.11013638973236084
15,2012-01-30 02:07:00,The stock carries a Zacks #3 Rank (Hold rating) in the short run.,0.2663762867450714,0.012906438671052456,0.7207172513008118,neutral,0.253469854593277
16,2012-01-30 02:07:00,"Although the company is facing patent expirations for many of its key drugs, we believe Warner Chilcott's diversified product base will help withstand the generic threat.",0.9170784950256348,0.013551408424973488,0.06937010586261749,positive,0.9035270810127258
17,2012-01-30 02:07:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
18,2012-01-30 02:07:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
